Interleukin-10 Gene Transfer in Rat Limbal Transplantation

Abstract

Under the conditions tested in the present model, both the AV and the LV vector systems were able to transfect limbal graft tissue ex vivo with biologically active IL-10, leading to delayed rejection compared to the controls.

Ocular Gene Therapy: Literature Review

“…Ad has turn out to be an efficient vehicle for ocular gene remedy for the reason that it is utilized to deal with short-term adjustments in gene expression [12]. Delivery of genes coding for interleukins and different cytokines, sFLT-1, c-Met, and different therapeutic genes by way of Ad has furnished cure of a number of conditions such as corneal neovascularization, limbal graft rejection, and wound healing in specific human and animal models [13][14][15]. Unfortunately, Ad vectors can also nonetheless keep the capability to set off adaptive and innate immunity producing adverse outcomes such as cytotoxic T-cell response [16].…”

“…Clinically pertinent equine infectious anemia virus (EIAV)-derived lentivirus has proven success in transgene transport of endostatin and angiostatin genes to inhibit corneal neovascularization [39]. Delivery of interleukin-10 gene by using lentiviral vectors extensively extended survival of corneal grafts [15]. Furthermore, subepithelial fibrosis in rat corneal stroma used to be substantially decreased by using Smad7 gene expression.…”

“…More recently, Ad and lentiviral vectors have been used to transduce limbal graft tissue ex vivo with biologically lively IL-10, main to delayed rejection in rats [15]. In addition to IL-10 gene transfer, blockading of pro-inflammatory IL-12 with the aid of nearby overexpression of the IL-12 p40 inhibitory subunit additionally extended sheep corneal graft survival [198].…”

Gene Therapy in the Anterior Eye Segment

“…Ad has become an efficient vehicle for ocular gene therapy since it is utilized to treat short-term alterations in gene expression [12]. Delivery of genes coding for interleukins and other cytokines, sFLT-1, c-Met, and other therapeutic genes via Ad has provided treatment of various conditions such as corneal neovascularization, limbal graft rejection, and wound healing in different human and animal models [13][14][15]. Unfortunately, Ad vectors may still retain the ability to trigger adaptive and innate immunity generating adverse effects such as cytotoxic T-cell response [16].…”

“…Clinically pertinent equine infectious anemia virus (EIAV)-derived lentivirus has shown success in transgene delivery of endostatin and angiostatin genes to inhibit corneal neovascularization [39]. Delivery of interleukin-10 gene via lentiviral vectors significantly increased survival of corneal grafts [15]. Furthermore, subepithelial fibrosis in rat corneal stroma was greatly reduced by Smad7 gene expression.…”